Phase 3 N=2,028 Radiation Therapy With or Without Antiandrogen Therapy in Treating Patients With Stage I or Stage II Prostate Cancer
Prostate Cancer
Primary: Overall Survival Rate (10-year) — 61.9; 56.8 percentage of patients — p=0.0309
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=150 Gabapentin Treatment of Cannabis Dependence
Cannabis Dependence · Cannabis Withdrawal · Cognitive Deficits
Primary: Percentage of Negative Urinary Drug Screens (UDS) for Cannabis at 12 Weeks Following Administration of Gabapentin or Placebo During the Double Blind Period — 11.22…
N/A N=16 Pilot and Feasibility Study for the Treatment of Pre-diabetes in Patients With Cystic Fibrosis
Cystic Fibrosis Related Diabetes · Pancreatic Insufficiency
Primary: BMI — 19.63; 21.19 Kg/m^2
Phase 2 N=74 Zonisamide Augmentation of Varenicline Treatment for Smoking Cessation
Nicotine Dependence
Primary: Percent Participants Abstinent From Smoking During Study Weeks 7-10 — 5; 6 Participants
Phase 2 N=25 Improving Buprenorphine Detoxification Outcomes With Isradipine
Opioid Dependence
Primary: Change Over Time in Illicit Opioid Use Via Urine Toxicology Screens During Buprenorphine Taper (Wks 5-6) — -1.25; -0.36 opioid-positive urine — p=.42
Phase 2 N=118 Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
Hepatoblastoma · Previously Treated Childhood Rhabdomyosarcoma · Recurrent Childhood Acute Lymphoblastic Leukemia
Primary: Number of Participants With Overall Response — 0; 1; 0; 0 Patients
Phase 3 N=391 Study to Evaluate the Efficacy and Safety of Hydrocodone Bitartrate Extended-Release Tablets (CEP-33237) for Relief of Moderate to Severe Pain in Patients With Osteoarthritis or Low Back Pain Who Require Opioid Treatment for an Extended Period of Time
Chronic Pain
Primary: Change From Baseline to Week 12 in Weekly Average Pain Intensity (wAPI) — 0.14; -0.22 units on a scale — p=0.134
Phase 2 N=56 Cardio-respiratory Events and Inflammatory Response After Primary Immunization in Preterm Infants
Complication Due to Immunization
Primary: The Change in the Number of CRE (Extracted From Printed Monitoring Tracings Compared to Noted Nurses' Surveillance) Following the First Dose of Pentavalent Vaccine in…
Phase 2 N=463 Investigational Device Exemption Study to Determine the Safety and Efficacy of the Astron and Pulsar Stents
Peripheral Artery Disease · Peripheral Vascular Disease
Primary: Effectiveness Endpoint for the Pulsar Stent: Primary Patency — 66.8 Percentage of participants
Phase 3 N=573 Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma
Carcinoma, Hepatocellular
Primary: Overall Survival (OS) — 237; 323 days — p== 0.000017
N/A N=10 Palonosetron and Hydroxyzine to Reduce Opioid Withdrawal
Substance-Related Disorders
Primary: OOWS Score — 3.5; 1.0; 0 units on a scale (OOWS Scale) — p=0.0001
N/A N=22 Effects of a Combined Transcranial Magnetic Stimulation (TMS) and Cognitive Training in Alzheimer Patients
Alzheimer's Disease
Primary: Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog) — 1.79; -0.20; -0.66 percentage change
Phase 4 N=323 Foley With Oxytocin Versus Foley no Oxytocin for Induction of Labor
Labor; Forced or Induced, Affecting Fetus or Newborn
Primary: Delivery Rate — 40; 58; 48; 62 Participants
N/A N=8 Cerebellar rTMS for the Treatment of Schizophrenic Patients
Schizophrenia
Primary: Adverse Events — 1 event
Phase 2 N=72 Citrulline in Severe Sepsis
Severe Sepsis · Acute Lung Injury
Primary: Vasopressor Dependency Index — 50.0; 44.4; 49.0 mmHg/catecholamine index — p=0.86